Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)

Phase 2 Unknown 300 enrolled aRigen Pharmaceuticals, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

A multi-center, randomized, 4-arm, placebo-controlled, double-blind efficacy study of ARYS-01 (sorivudine) cream 3%.

Evaluation	Drug	Modality	Dose	Route
Subject	Sorivudine	Small molecule	3 %	Topical
Subject	Valaciclovir	Unknown	1 g	Oral